Behfar Ehdaie, MD
Urology · New York, NYNPI 1629281423
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,464 of the $22,086 with a category attached, or 83.6%. EDAP Technomed Inc accounts for 62.3% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $10,029, more than ten times the $355 reported in 2019.
Across 29 payments — averaging $761.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EDAP Technomed Inc$14K
- Koelis Inc.$8K
- Insightec,ltd$355
- Blue Earth Diagnostics$175
- Intuitive Surgical$157
- Antares Pharma, Inc.$44
Across 5 payments — averaging $77,060 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insightec,ltd$385K
What the payments were for
- Consulting fees$18,46484%
- Travel & lodging$1,7988%
- Food & beverage$1,6678%
- Education$1571%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EDAP Technomed Inc | 21 | $13,756 |
| Koelis Inc. | 3 | $7,600 |
| Insightec,ltd | 1 | $355 |
| Blue Earth Diagnostics | 2 | $175 |
| Intuitive Surgical | 1 | $157 |
| Antares Pharma, Inc. | 1 | $44 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FOCAL ONE$9,911
- Trinity 3D Prostate Suite$7,600
- POSLUMA$159
- Da Vinci Surgical System$157
How this compares
$22,086 in reported general payments places this provider in the 85th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 121 | $1,209 |
| Finasteride | 29 | $320 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $15 |
Paid to pharmacies, not to this prescriber.
Other urology in New York
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Ketan BadaniNew York$285K
- Michael GrassoNew York$284K
- Mantu GuptaNew York$229K
- Robin SmithNew York$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.